Literature DB >> 28386095

TIMP-1 is upregulated, but not essential in hepatic fibrogenesis and carcinogenesis in mice.

Nina D Thiele1, Jan W Wirth1, David Steins1, Anja C Koop1, Harald Ittrich2, Ansgar W Lohse1, Johannes Kluwe3.   

Abstract

Tissue inhibitor of metalloproteinases-1 (TIMP-1) is upregulated during hepatic fibrogenesis and considered to promote fibrosis in the injured liver by inhibition of matrix metalloproteases (MMP) and degradation of extracellular matrix. Moreover, TIMP-1 displays anti-apoptotic properties, in patients with hepatocellular carcinoma (HCC) TIMP-1 serum levels are elevated and high TIMP-1 expression levels in HCC are associated with a poor prognosis. Therefore, TIMP-1 could functionally link fibrogenesis and carcinogenesis in the liver. The aim of our study was to characterize the role of TIMP-1 in hepatic fibrogenesis and carcinogenesis. Experimental hepatic fibrogenesis as well as diethylnitrosamine (DEN) -induced hepatocarcinogenesis were studied in TIMP-1-deficient mice and wild type littermates. Hepatic TIMP-1 expression was upregulated following induction of liver fibrosis by bile duct ligation (BDL) or by carbon tetrachloride (CCl4). Unexpectedly, in comparison to wild type littermates, TIMP-1-deficient mice were not protected from liver fibrosis induced by BDL or CCl4. TIMP-1 expression was significantly higher in HCC nodules than in surrounding liver tissue. However, experimental hepatic carcinogenesis was similar in TIMP-1-deficient mice and wild type littermates following DEN-treatment or combined treatment with DEN and CCl4. Therefore we concluded that TIMP-1 is not essential for hepatic fibrogenesis and carcinogenesis in mice.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28386095      PMCID: PMC5428806          DOI: 10.1038/s41598-017-00671-1

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  35 in total

1.  Gelatinases and their tissue inhibitors in ovarian tumors; TIMP-1 is a predictive as well as a prognostic factor.

Authors:  M Rauvala; U Puistola; T Turpeenniemi-Hujanen
Journal:  Gynecol Oncol       Date:  2005-08-19       Impact factor: 5.482

Review 2.  Tissue inhibitor of metalloproteinase 1 (TIMP-1) as a biomarker in gastric cancer: a review.

Authors:  Mie Grunnet; Morten Mau-Sørensen; Nils Brünner
Journal:  Scand J Gastroenterol       Date:  2013-07-08       Impact factor: 2.423

3.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

Review 4.  Hepatocellular carcinoma: epidemiology, risk factors, and screening.

Authors:  Morris Sherman
Journal:  Semin Liver Dis       Date:  2005       Impact factor: 6.115

5.  Targeted mutagenesis of Timp-1 reveals that lung tumor invasion is influenced by Timp-1 genotype of the tumor but not by that of the host.

Authors:  P D Soloway; C M Alexander; Z Werb; R Jaenisch
Journal:  Oncogene       Date:  1996-12-05       Impact factor: 9.867

6.  Serum tissue inhibitor of metalloproteinases in patients with chronic liver disease and with hepatocellular carcinoma.

Authors:  Y Murawaki; H Yamamoto; H Kawasaki; H Shima
Journal:  Clin Chim Acta       Date:  1993-09-17       Impact factor: 3.786

7.  Antifibrotic effects of a tissue inhibitor of metalloproteinase-1 antibody on established liver fibrosis in rats.

Authors:  Christopher J Parsons; Blair U Bradford; Clark Q Pan; Ellen Cheung; Michael Schauer; Andreas Knorr; Barbara Krebs; Sabine Kraft; Stefan Zahn; Bodo Brocks; Nikki Feirt; Baisong Mei; Myung-Sam Cho; Roopa Ramamoorthi; Greg Roldan; Paul Ng; Peggy Lum; Claudia Hirth-Dietrich; Adrian Tomkinson; David A Brenner
Journal:  Hepatology       Date:  2004-11       Impact factor: 17.425

8.  Gene expression profiles during hepatic stellate cell activation in culture and in vivo.

Authors:  Samuele De Minicis; Ekihiro Seki; Hiroshi Uchinami; Johannes Kluwe; Yonghui Zhang; David A Brenner; Robert F Schwabe
Journal:  Gastroenterology       Date:  2007-02-21       Impact factor: 22.682

9.  Prognostic significance of MMP-9 and TIMP-1 serum and tissue expression in breast cancer.

Authors:  Zheng-Sheng Wu; Qiang Wu; Jiu-Hua Yang; Hong-Qun Wang; Xiang-Dong Ding; Feng Yang; Xiao-Chun Xu
Journal:  Int J Cancer       Date:  2008-05-01       Impact factor: 7.396

10.  Tissue inhibitor of metalloproteinases-1 promotes liver metastasis by induction of hepatocyte growth factor signaling.

Authors:  Charlotte Kopitz; Michael Gerg; Obul Reddy Bandapalli; Dilek Ister; Caroline J Pennington; Stephanie Hauser; Christin Flechsig; Hans-Willi Krell; Dalibor Antolovic; Keith Brew; Hideaki Nagase; Manfred Stangl; Claus W Hann von Weyhern; Björn L D M Brücher; Karsten Brand; Lisa M Coussens; Dylan R Edwards; Achim Krüger
Journal:  Cancer Res       Date:  2007-09-15       Impact factor: 12.701

View more
  12 in total

1.  Genomics and metabolomics of early-stage thioacetamide-induced liver injury: An interspecies study between guinea pig and rat.

Authors:  Patric Schyman; Richard L Printz; Venkat R Pannala; Mohamed Diwan M AbdulHameed; Shanea K Estes; Chiyo Shiota; Kelli Lynn Boyd; Masakazu Shiota; Anders Wallqvist
Journal:  Toxicol Appl Pharmacol       Date:  2021-09-04       Impact factor: 4.219

2.  Human amniotic mesenchymal stem cells-derived IGFBP-3, DKK-3, and DKK-1 attenuate liver fibrosis through inhibiting hepatic stellate cell activation by blocking Wnt/β-catenin signaling pathway in mice.

Authors:  Quan-Wen Liu; Yan-Min Ying; Jia-Xin Zhou; Wen-Jie Zhang; Zhao-Xiao Liu; Bing-Bing Jia; Hao-Cheng Gu; Chu-Yu Zhao; Xiao-Hui Guan; Ke-Yu Deng; Hong-Bo Xin
Journal:  Stem Cell Res Ther       Date:  2022-06-03       Impact factor: 8.079

3.  Anti-CD47 antibody treatment attenuates liver inflammation and fibrosis in experimental non-alcoholic steatohepatitis models.

Authors:  Taesik Gwag; Eric Ma; Changcheng Zhou; Shuxia Wang
Journal:  Liver Int       Date:  2022-02-15       Impact factor: 8.754

Review 4.  Non-alcoholic Steatohepatitis Pathogenesis, Diagnosis, and Treatment.

Authors:  Bo Zhu; Siu-Lung Chan; Jack Li; Kathryn Li; Hao Wu; Kui Cui; Hong Chen
Journal:  Front Cardiovasc Med       Date:  2021-09-07

5.  Therapeutic Potential of OMe-PS-miR-29b1 for Treating Liver Fibrosis.

Authors:  Virender Kumar; Vinod Kumar; Jiangtao Luo; Ram I Mahato
Journal:  Mol Ther       Date:  2018-09-01       Impact factor: 11.454

6.  Distinct hepatic immunological patterns are associated with the progression or inhibition of hepatocellular carcinoma.

Authors:  Faridoddin Mirshahi; Hussein F Aqbi; Madison Isbell; Saeed H Manjili; Chunqing Guo; Mulugeta Saneshaw; Dipankar Bandyopadhyay; Mikhail Dozmorov; Archit Khosla; Katy Wack; Oscar M Carrasco-Zevallos; Michael O Idowu; Xiang-Yang Wang; Arun J Sanyal; Masoud H Manjili
Journal:  Cell Rep       Date:  2022-03-01       Impact factor: 9.995

7.  Zwitterionically modified alginates mitigate cellular overgrowth for cell encapsulation.

Authors:  Qingsheng Liu; Alan Chiu; Long-Hai Wang; Duo An; Monica Zhong; Alexandra M Smink; Bart J de Haan; Paul de Vos; Kevin Keane; Andreas Vegge; Esther Y Chen; Wei Song; Wendy F Liu; James Flanders; Claude Rescan; Lars Groth Grunnet; Xi Wang; Minglin Ma
Journal:  Nat Commun       Date:  2019-11-20       Impact factor: 14.919

8.  Salacia chinensis L. Stem Extract Exerts Antifibrotic Effects on Human Hepatic Stellate Cells Through the Inhibition of the TGF-β1-Induced SMAD2/3 Signaling Pathway.

Authors:  Mattareeyapar Phaosri; Salinee Jantrapirom; Mingkwan Na Takuathung; Noppamas Soonthornchareonnon; Seewaboon Sireeratawong; Pensiri Buacheen; Pornsiri Pitchakarn; Wutigri Nimlamool; Saranyapin Potikanond
Journal:  Int J Mol Sci       Date:  2019-12-13       Impact factor: 5.923

Review 9.  Targeting Cancer Associated Fibroblasts in Liver Fibrosis and Liver Cancer Using Nanocarriers.

Authors:  Leonard Kaps; Detlef Schuppan
Journal:  Cells       Date:  2020-09-03       Impact factor: 6.600

10.  Fibroblast Growth Factor 21 (FGF21) Administration Sex-Specifically Affects Blood Insulin Levels and Liver Steatosis in Obese Ay Mice.

Authors:  Elena Makarova; Antonina Kazantseva; Anastasia Dubinina; Elena Denisova; Tatiana Jakovleva; Natalia Balybina; Nataliya Bgatova; Konstantin Baranov; Nadezhda Bazhan
Journal:  Cells       Date:  2021-12-07       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.